FDA grants orphan-drug review status to Biogen leukemia drug

02/7/2007 | San Diego Union-Tribune

The FDA granted Biogen Idec orphan-drug status and accelerated review of its leukemia drug, lumiliximab, for treating the relatively rare chronic lymphocytic leukemia. The drug is in a Phase III trial comparing its use in combination with chemotherapy and the firm's Rituxan against just the combination of Rituxan and chemotherapy.

View Full Article in:

San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX